Donald Jeffrey Keyser - 12 May 2026 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Reporting relationship: Director
Issuer ticker: LTRN
Reported as of: 12 May 2026
Net transaction value: +$100,001
SEC form: 4
Accepted by SEC: 14 May 2026, 16:10:08 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Donald Jeffrey Keyser

Key filing fact

Donald Jeffrey Keyser filed Form 4 for Lantern Pharma Inc. (LTRN) on 14 May 2026.

Key facts

This page summarizes Donald Jeffrey Keyser's Form 4 filing for Lantern Pharma Inc. (LTRN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 May 2026, 16:10.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: +$100,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001393516 Primary reporting owner

KEYSER D JEFFREY

Relationship: Director
Address: 1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS
Signature: /s/ Donald Jeffrey Keyser
Signature date: 14 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LTRN transaction

Common stock, $0.001 par value

Purchase

Transaction value: $100,001
Shares: +48,544
Change %: +106%
Price: $2.06
Shares after: 94,303
Date: 12 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LTRN transaction Derivative

Common stock purchase warrant (Right to Buy)

Purchase

Transaction value
Shares: -48,544
Change %: -50%
Price: $0.000000^*
Shares after: 48,544
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,544
Exercise price: $2.27
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026.